By Kai Zheng –Stanford Cancer Institute –
Following the FDA approval of Orca-T, the field of bone marrow and stem cell transplantation has reached a long-sought watershed moment.
For decades, cancer scientists have wrestled with a conundrum regarding stem cell transplants: the same treatment capable of curing aggressive blood cancers can also trigger an overactive immune system that damages healthy tissues and organ functioning. Now, in a revolutionary study known as the Precision-T trial, Stanford Cancer Institute member and study lead author Everett Meyer, MD, PhD, professor of medicine, and Stanford Cancer Institute member Robert Negrin, MD, professor of medicine and former chief of the Stanford Division of Blood and Bone Marrow Transplantation & Cellular Therapy, have delivered a breakthrough to address this problem.
